Pharmaceuticals, Biotechnology and Life Sciences
HOUSTON–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical…
Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to…
—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients…
Joins Experienced Team to Accelerate Global Launch of the new Sonata® 2 System REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare…
Animal model operations to be transferred to Envigo ownership Divestment in line with Horizon’s corporate strategy to focus on its…
— Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the…
22nd Century Builds Strong Momentum for its Very Low Nicotine Content Tobacco and Makes Significant Progress in the Development of…
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to…
— Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced…
Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion…